306 related articles for article (PubMed ID: 15701824)
41. Dual-targeting topotecan liposomes modified with tamoxifen and wheat germ agglutinin significantly improve drug transport across the blood-brain barrier and survival of brain tumor-bearing animals.
Du J; Lu WL; Ying X; Liu Y; Du P; Tian W; Men Y; Guo J; Zhang Y; Li RJ; Zhou J; Lou JN; Wang JC; Zhang X; Zhang Q
Mol Pharm; 2009; 6(3):905-17. PubMed ID: 19344115
[TBL] [Abstract][Full Text] [Related]
42. Strategies for transporting nanoparticles across the blood-brain barrier.
Zhang TT; Li W; Meng G; Wang P; Liao W
Biomater Sci; 2016 Feb; 4(2):219-29. PubMed ID: 26646694
[TBL] [Abstract][Full Text] [Related]
43. Recent Strategies for Targeted Brain Drug Delivery.
Ogawa K; Kato N; Kawakami S
Chem Pharm Bull (Tokyo); 2020; 68(7):567-582. PubMed ID: 32611994
[TBL] [Abstract][Full Text] [Related]
44. Modification of the blood-brain barrier in the chemotherapy of malignant brain tumors.
Neuwelt EA; Rapoport SI
Fed Proc; 1984 Feb; 43(2):214-9. PubMed ID: 6692941
[TBL] [Abstract][Full Text] [Related]
45. Recent advances in brain tumor-targeted nano-drug delivery systems.
Liu Y; Lu W
Expert Opin Drug Deliv; 2012 Jun; 9(6):671-86. PubMed ID: 22607535
[TBL] [Abstract][Full Text] [Related]
46. Barriers to Effective Drug Treatment for Brain Metastases: A Multifactorial Problem in the Delivery of Precision Medicine.
Kim M; Kizilbash SH; Laramy JK; Gampa G; Parrish KE; Sarkaria JN; Elmquist WF
Pharm Res; 2018 Jul; 35(9):177. PubMed ID: 30003344
[TBL] [Abstract][Full Text] [Related]
47. Evaluation of permeability, doxorubicin delivery, and drug retention in a rat brain tumor model after ultrasound-induced blood-tumor barrier disruption.
Park J; Aryal M; Vykhodtseva N; Zhang YZ; McDannold N
J Control Release; 2017 Mar; 250():77-85. PubMed ID: 27742444
[TBL] [Abstract][Full Text] [Related]
48. Crossing the Blood-Brain Barrier: Advances in Nanoparticle Technology for Drug Delivery in Neuro-Oncology.
Hersh AM; Alomari S; Tyler BM
Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35456971
[TBL] [Abstract][Full Text] [Related]
49. Penetration of blood-brain barrier and antitumor activity and nerve repair in glioma by doxorubicin-loaded monosialoganglioside micelles system.
Zou D; Wang W; Lei D; Yin Y; Ren P; Chen J; Yin T; Wang B; Wang G; Wang Y
Int J Nanomedicine; 2017; 12():4879-4889. PubMed ID: 28744122
[TBL] [Abstract][Full Text] [Related]
50. How to Make Anticancer Drugs Cross the Blood-Brain Barrier to Treat Brain Metastases.
Angeli E; Nguyen TT; Janin A; Bousquet G
Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31861465
[TBL] [Abstract][Full Text] [Related]
51. Osmotic blood-brain barrier modification and combination chemotherapy: concurrent tumor regression in areas of barrier opening and progression in brain regions distant to barrier opening.
Neuwelt EA; Hill SA; Frenkel EP
Neurosurgery; 1984 Sep; 15(3):362-6. PubMed ID: 6090973
[TBL] [Abstract][Full Text] [Related]
52. Overview of Current Drug Delivery Methods Across the Blood-Brain Barrier for the Treatment of Primary Brain Tumors.
Haumann R; Videira JC; Kaspers GJL; van Vuurden DG; Hulleman E
CNS Drugs; 2020 Nov; 34(11):1121-1131. PubMed ID: 32965590
[TBL] [Abstract][Full Text] [Related]
53. Breaking down barriers to treat a patient with a germinoma: a case study.
Bell S
J Neurosci Nurs; 2004 Aug; 36(4):195-9. PubMed ID: 15366544
[TBL] [Abstract][Full Text] [Related]
54. Local convection-enhanced delivery of chemotherapeutic agent transiently opens blood-brain barrier and improves efficacy of systemic chemotherapy in intracranial xenograft tumor model.
Nakamura T; Saito R; Sugiyama S; Sonoda Y; Kumabe T; Tominaga T
Cancer Lett; 2011 Nov; 310(1):77-83. PubMed ID: 21763069
[TBL] [Abstract][Full Text] [Related]
55. Blood brain barrier: a challenge for effectual therapy of brain tumors.
Bhowmik A; Khan R; Ghosh MK
Biomed Res Int; 2015; 2015():320941. PubMed ID: 25866775
[TBL] [Abstract][Full Text] [Related]
56. 19th Society for Neuro-Oncology Annual Meeting.
Collingridge D
Lancet Oncol; 2015 Jan; 16(1):18. PubMed ID: 25638541
[No Abstract] [Full Text] [Related]
57. Delivery of therapeutic agents to the central nervous system: the problems and the possibilities.
Begley DJ
Pharmacol Ther; 2004 Oct; 104(1):29-45. PubMed ID: 15500907
[TBL] [Abstract][Full Text] [Related]
58. Updates from the 2013 Society for Neuro-Oncology annual and World Federation for Neuro-Oncology quadrennial meeting.
Lukas RV; Amidei C
Tumori; 2014; 100(3):358-62. PubMed ID: 25076251
[TBL] [Abstract][Full Text] [Related]
59. Chemotherapy delivery issues in central nervous system malignancy: a reality check.
Muldoon LL; Soussain C; Jahnke K; Johanson C; Siegal T; Smith QR; Hall WA; Hynynen K; Senter PD; Peereboom DM; Neuwelt EA
J Clin Oncol; 2007 Jun; 25(16):2295-305. PubMed ID: 17538176
[TBL] [Abstract][Full Text] [Related]
60. Molecular neuro-oncology and the challenge of the blood-brain barrier.
Aiken R
Semin Oncol; 2014 Aug; 41(4):438-445. PubMed ID: 25173137
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
